drugset

drugset / Trial / NCT03009019

Efficacy, Tolerability, and Safety of DFN-15

NCT03009019 ↗

Phase 3 Completed 631 enrolled BioDelivery Sciences International Dr. Reddy's Laboratories Limited · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

Efficacy, Tolerability, and Safety of DFN-15 in episodic migraine with or without aura, being conducted at multiple centers in the United States

Timeline

Start: 2016-12
Primary completion: 2017-11
Completion: 2019-05

Publications

Lipton RB, Munjal S, Tepper SJ, Iaconangelo C, Serrano D. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Tolerability, and Safety of Celecoxib Oral Solution (ELYXYB) in Acute Treatment of Episodic Migraine with or without Aura. J Pain Res. 2021 Aug 19;14:2529-2542. doi: 10.2147/JPR.S322292. eCollection 2021.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Celecoxib	Other / unclassified	120 mg	Oral

Indications